COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Mehdi Mesri, M.Med.Sci., Ph.D.

Program Director

Mehdi Mesri

Dr. Mesri provides leadership in integrating emerging technologies for the development of cancer protein diagnostics and therapeutics.  He coordinates activities with NCI's Small Business Innovation Research (SBIR) Office and manages OCCPR proteomics investigator grants.  Prior to the NCI, Dr. Mesri served as a principal scientist/projects leader in the Department of Protein Therapeutics at Celera.  There, he used mass spectrometry technologies to discover and validate biologic antibody targets in oncology, including prostate and lung cancers and angiogenesis.  Prior to that, Dr. Mesri was a project leader at CuraGen Corporation, where he investigated genomically-derived high value protein drugs and fully human monoclonal antibody targets for cancer and immunology/inflammation programs, among other responsibilities.  Dr. Mesri holds a BSc. in Biomedical Sciences (1990) from the University of Bradford (UK), a M.Med.Sci. degree in clinical pathology (1991) from the University of Sheffield (UK), and a Ph.D. degree in immunology (1995) from the University of Aberdeen (UK).